Study S002107

Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01931982
Acronym: EGOFIP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: COMPLETED
Enrollment: 20
Start: 2013-05
Primary completion: 2014-04
Lead sponsor: Bispebjerg Hospital
Conditions: Type 2 Diabetes; Microvascular Dysfunction
Interventions: DRUG:Victoza
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-005013-38

Registered primary outcomes

Change in coronary flow reserve (CFR) [CFR is measured at baseline and after 10 weeks of intervention]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018665	Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Faber R, Cardiovascular diabetology	2015	Randomized trial	PMID 25896352 DOI	cites ClinicalTrials.gov:NCT01931982; registry reference DERIVED:25896352